Eliem Therapeutics, Inc. (NASDAQ:ELYM) Forecasted to Post FY2022 Earnings of ($1.86) Per Share

Eliem Therapeutics, Inc. (NASDAQ:ELYMGet Rating) – Stock analysts at HC Wainwright raised their FY2022 earnings per share estimates for Eliem Therapeutics in a report released on Tuesday, November 15th. HC Wainwright analyst D. Tsao now forecasts that the company will post earnings per share of ($1.86) for the year, up from their previous forecast of ($2.05). HC Wainwright has a “Buy” rating and a $6.00 price target on the stock. The consensus estimate for Eliem Therapeutics’ current full-year earnings is ($1.84) per share. HC Wainwright also issued estimates for Eliem Therapeutics’ Q4 2022 earnings at ($0.47) EPS, Q4 2022 earnings at ($0.47) EPS, Q1 2023 earnings at ($0.53) EPS, Q2 2023 earnings at ($0.55) EPS, Q2 2023 earnings at ($0.55) EPS, Q3 2023 earnings at ($0.21) EPS, Q4 2023 earnings at ($0.30) EPS, FY2023 earnings at ($1.43) EPS, FY2024 earnings at ($1.44) EPS, FY2024 earnings at ($1.44) EPS, FY2025 earnings at ($1.63) EPS and FY2026 earnings at ($1.05) EPS.

ELYM has been the subject of several other reports. Stifel Nicolaus dropped their target price on Eliem Therapeutics from $35.00 to $8.00 in a research report on Tuesday, August 2nd. SVB Leerink dropped their target price on Eliem Therapeutics from $9.00 to $4.00 and set an “outperform” rating for the company in a research report on Tuesday, August 16th.

Eliem Therapeutics Stock Down 8.3 %

NASDAQ:ELYM opened at $2.66 on Thursday. The stock’s 50-day simple moving average is $3.18 and its 200 day simple moving average is $3.36. The firm has a market capitalization of $70.67 million, a PE ratio of -1.45 and a beta of 1.28. Eliem Therapeutics has a twelve month low of $2.52 and a twelve month high of $18.83.

Eliem Therapeutics (NASDAQ:ELYMGet Rating) last released its quarterly earnings data on Monday, August 15th. The company reported ($0.52) earnings per share for the quarter, missing the consensus estimate of ($0.47) by ($0.05).

Hedge Funds Weigh In On Eliem Therapeutics

Several large investors have recently bought and sold shares of ELYM. Parkwood LLC raised its position in Eliem Therapeutics by 63.4% in the second quarter. Parkwood LLC now owns 67,202 shares of the company’s stock valued at $67,000 after purchasing an additional 26,069 shares during the last quarter. Chicago Partners Investment Group LLC raised its position in shares of Eliem Therapeutics by 77.9% during the first quarter. Chicago Partners Investment Group LLC now owns 22,209 shares of the company’s stock worth $81,000 after acquiring an additional 9,723 shares during the last quarter. Qube Research & Technologies Ltd bought a new position in shares of Eliem Therapeutics during the first quarter worth about $133,000. Atom Investors LP raised its position in shares of Eliem Therapeutics by 154.9% during the third quarter. Atom Investors LP now owns 67,074 shares of the company’s stock worth $217,000 after acquiring an additional 40,765 shares during the last quarter. Finally, Millennium Management LLC bought a new position in shares of Eliem Therapeutics during the second quarter worth about $272,000. 63.51% of the stock is currently owned by institutional investors.

Eliem Therapeutics Company Profile

(Get Rating)

Eliem Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in chronic pain, neuropsychiatry, epilepsy, and other disorders of the peripheral and central nervous systems. Its two lead drug candidates are ETX-810 for chronic pain, which is in Phase IIa clinical trial; and ETX-155 for the treatment of major depressive disorder, perimenopausal depression, and focal onset seizures that is in Phase I clinical trial.

Recommended Stories

Earnings History and Estimates for Eliem Therapeutics (NASDAQ:ELYM)

Receive News & Ratings for Eliem Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eliem Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.